
CLAIMS

1. A compound of the following formula (1) in crystalline form:



(1)

~~2. The crystalline compound of formula (1) according to claim 1,~~ having an X-ray powder diffraction pattern comprising a peak at 9.6 degrees 2θ (± 0.2 degrees 2θ) when measured using CuKα radiation.

~~3~~2. The crystalline compound according to claim ~~2~~1, wherein the X-ray powder diffraction pattern further comprises a peak at 19.8 degrees 2θ (± 0.2 degrees 2θ) when measured using CuKα radiation.

~~4~~3. A crystalline compound of formula (1) according to claim 1, having an X-ray powder diffraction pattern comprising peaks at 4.8, 6.8, 9.6, 13.6, 17.3, 19.8 and 24.5 degrees 2θ (± 0.2 degrees 2θ) when measured using CuKα radiation.

~~5~~4. Use of the crystalline compound of formula (1) according to claim 1 or a mixture thereof with the sodium salt of the compound of formula (1) for the preparation of a pharmaceutical composition to treat a Hepatitis C viral infection in a mammal.